Tin-117m somatostatin receptor binding compounds and methods
Tin-117m somatoostatin analogs or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic. Also, if desired, it can be administered at a dose that is necrotic and/or induces necrosis, but only to cells within 290 microns of the tin-117m atom. A novel somatostatin analog is also disclosed, as well as novel methods to produce the tin labeled analogs and antagonists.
1. A method of treating a patient having a tumor having somatostatin receptors comprising:
administering to said patient an effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE.
2. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 200 millicuries.
3. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 100 millicuries.
4. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 32 millicuries.
5. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 20 millicuries.
6. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 15 millicuries.
7. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 12 millicuries.
8. The method of claim 1 , wherein the effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE is from about 0.5 millicuries to about 5 millicuries.
9. The method of claim 1 , wherein the tin-117m-benzyl-isothiocyanato-DOTA-TATE is administered intravenously.
10. The method of claim 1 , further comprising repeating the administering to said patient an effective amount of tin-117m-benzyl-isothiocyanato-DOTA-TATE after passage of a time period.
11. The method of claim 10 , wherein the time period is about 4 weeks.